Zobrazeno 1 - 10
of 38
pro vyhledávání: '"Kristen J. Pierce"'
Autor:
Josep Tabernero, Irene Braña, Maria Alsina, Jorge D. Gallo, Brett E. Houk, Lixin Han, Kristen J. Pierce, Gary Borzillo, Robert Millham, Susan S. Pandya, Eunice L. Kwak, James Spicer, Johanna Bendell, Julian R. Molina, Katherine M. Bell-McGuinn, Geoffrey I. Shapiro
Supplemental Table 7. Results of the pharmacodynamic analysis of tumor-associated biomarkers following treatment with PF-05212384
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b46c240c8b64ebf0330fc492627ae09
https://doi.org/10.1158/1078-0432.22456157
https://doi.org/10.1158/1078-0432.22456157
Autor:
Josep Tabernero, Irene Braña, Maria Alsina, Jorge D. Gallo, Brett E. Houk, Lixin Han, Kristen J. Pierce, Gary Borzillo, Robert Millham, Susan S. Pandya, Eunice L. Kwak, James Spicer, Johanna Bendell, Julian R. Molina, Katherine M. Bell-McGuinn, Geoffrey I. Shapiro
Supplemental Table 6. Changes observed in metabolic biomarker levels following treatment with PF-05212384
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::517bb1bc2edce5bc332ca3b1b3d79d69
https://doi.org/10.1158/1078-0432.22456160.v1
https://doi.org/10.1158/1078-0432.22456160.v1
Autor:
Josep Tabernero, Irene Braña, Maria Alsina, Jorge D. Gallo, Brett E. Houk, Lixin Han, Kristen J. Pierce, Gary Borzillo, Robert Millham, Susan S. Pandya, Eunice L. Kwak, James Spicer, Johanna Bendell, Julian R. Molina, Katherine M. Bell-McGuinn, Geoffrey I. Shapiro
Supplemental Table 1. Additional study results on treatment-related adverse events at dose levels below the maximum tolerated dose
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::126227ee45601a14d10657779d0ada10
https://doi.org/10.1158/1078-0432.22456175.v1
https://doi.org/10.1158/1078-0432.22456175.v1
Autor:
Josep Tabernero, Irene Braña, Maria Alsina, Jorge D. Gallo, Brett E. Houk, Lixin Han, Kristen J. Pierce, Gary Borzillo, Robert Millham, Susan S. Pandya, Eunice L. Kwak, James Spicer, Johanna Bendell, Julian R. Molina, Katherine M. Bell-McGuinn, Geoffrey I. Shapiro
Supplemental Table 3. Cycle 1 results of the pharmacokinetic analysis of PF-05212384 administered at the maximum tolerated dose
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72f79cf89011c4a0210cc955c3f4cde0
https://doi.org/10.1158/1078-0432.22456169.v1
https://doi.org/10.1158/1078-0432.22456169.v1
Autor:
Josep Tabernero, Irene Braña, Maria Alsina, Jorge D. Gallo, Brett E. Houk, Lixin Han, Kristen J. Pierce, Gary Borzillo, Robert Millham, Susan S. Pandya, Eunice L. Kwak, James Spicer, Johanna Bendell, Julian R. Molina, Katherine M. Bell-McGuinn, Geoffrey I. Shapiro
Supplemental Table 2. Additional study results on treatment-related adverse events at dose levels above the maximum tolerated dose
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77c79d3f495a242cc7fefed02ad412ef
https://doi.org/10.1158/1078-0432.22456172.v1
https://doi.org/10.1158/1078-0432.22456172.v1
Autor:
Josep Tabernero, Irene Braña, Maria Alsina, Jorge D. Gallo, Brett E. Houk, Lixin Han, Kristen J. Pierce, Gary Borzillo, Robert Millham, Susan S. Pandya, Eunice L. Kwak, James Spicer, Johanna Bendell, Julian R. Molina, Katherine M. Bell-McGuinn, Geoffrey I. Shapiro
Purpose: To evaluate safety (primary endpoint), tolerability, pharmacokinetics, pharmacodynamic profile, and preliminary activity of the intravenous, pan-class I isoform PI3K/mTOR inhibitor PF-05212384 in patients with advanced solid tumors.Experimen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::003f2b2e15a90921cbad4234cbd0e0ae
https://doi.org/10.1158/1078-0432.c.6523223.v1
https://doi.org/10.1158/1078-0432.c.6523223.v1
Autor:
Josep Tabernero, Irene Braña, Maria Alsina, Jorge D. Gallo, Brett E. Houk, Lixin Han, Kristen J. Pierce, Gary Borzillo, Robert Millham, Susan S. Pandya, Eunice L. Kwak, James Spicer, Johanna Bendell, Julian R. Molina, Katherine M. Bell-McGuinn, Geoffrey I. Shapiro
Supplemental Table 5. presents a summary of the responses and clinical benefit observed in patients with advanced solid malignancies following treatment with PF-05212384.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69235013beb24dfb24087592f35a697e
https://doi.org/10.1158/1078-0432.22456163.v1
https://doi.org/10.1158/1078-0432.22456163.v1
Autor:
Giuseppe Curigliano, Geoffrey I. Shapiro, Rebecca S. Kristeleit, Albiruni R. Abdul Razak, Stephen Leong, Maria Alsina, Antonio Giordano, Karen A. Gelmon, Erica Stringer-Reasor, Ulka N. Vaishampayan, Mark Middleton, Anthony J. Olszanski, Hope S. Rugo, Kenneth A. Kern, Nuzhat Pathan, Rachelle Perea, Kristen J. Pierce, Sarah C. Mutka, Zev A. Wainberg
Publikováno v:
British journal of cancer. 128(1)
This Phase 1b study (B2151002) evaluated the PI3K/mTOR inhibitor gedatolisib (PF-05212384) in combination with other anti-tumour agents in advanced solid tumours.Patients with various malignancies were administered gedatolisib (90‒310 mg intravenou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e1818b1cd7a3a5f0aea8ef2fee63c16
https://pubmed.ncbi.nlm.nih.gov/36335217
https://pubmed.ncbi.nlm.nih.gov/36335217
Autor:
Giuseppe Curigliano, Geoffrey I. Shapiro, Rebecca S. Kristeleit, Albiruni R. Abdul Razak, Stephen Leong, Maria Alsina, Antonio Giordano, Karen A. Gelmon, Erica Stringer-Reasor, Ulka N. Vaishampayan, Mark Middleton, Anthony J. Olszanski, Hope S. Rugo, Kenneth A. Kern, Nuzhat Pathan, Rachelle Perea, Kristen J. Pierce, Sarah C. Mutka, Zev A. Wainberg
Publikováno v:
Br J Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb0c5887cbae60c074f6fb77bd92e82c
https://doi.org/10.1038/s41416-023-02161-w
https://doi.org/10.1038/s41416-023-02161-w
Autor:
Neal D. Shore, Thomas Powles, Jens Bedke, Matt D. Galsky, Evgeny Kopyltsov, Andrea Necchi, Joan Palou, Jennifer J. Vermette, Alison E. Randall, Kristen J. Pierce, Rossano Cesari, Gary D. Steinberg
Publikováno v:
Journal of Clinical Oncology. 40:TPS4614-TPS4614
TPS4614 Background: Bacillus Calmette-Guérin (BCG) therapy is the standard of care for high-risk non-muscle invasive bladder cancer (NMIBC) after transurethral resection of bladder tumor. However, disease recurrence or progression is common and pati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::42d6a59beb9e9150bf5a0809710bb240
https://doi.org/10.1200/jco.2022.40.16_suppl.tps4614
https://doi.org/10.1200/jco.2022.40.16_suppl.tps4614